155 related articles for article (PubMed ID: 19959799)
1. Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences.
Mangold KA; Wang V; Weissman SM; Rubinstein WS; Kaul KL
J Mol Diagn; 2010 Jan; 12(1):20-6. PubMed ID: 19959799
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue.
Adank MA; Brogi E; Bogomolniy F; Wadsworth EA; Lafaro KJ; Yee CJ; Kirchhoff T; Meijers-Heijboer EJ; Kauff ND; Boyd J; Offit K
Fam Cancer; 2006; 5(4):337-42. PubMed ID: 16724247
[TBL] [Abstract][Full Text] [Related]
3. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
4. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
5. A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing.
Zhang L; Kirchhoff T; Yee CJ; Offit K
J Mol Diagn; 2009 May; 11(3):176-81. PubMed ID: 19324993
[TBL] [Abstract][Full Text] [Related]
6. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
7. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
8. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
9. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
10. Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.
Zannini G; Facchini G; De Sio M; De Vita F; Ronchi A; Orditura M; Vietri MT; Ciardiello F; Franco R; Accardo M; Zito Marino F
Pathol Res Pract; 2023 Mar; 243():154336. PubMed ID: 36736144
[TBL] [Abstract][Full Text] [Related]
11. Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.
Petersen AH; Aagaard MM; Nielsen HR; Steffensen KD; Waldstrøm M; Bojesen A
Eur J Hum Genet; 2016 Aug; 24(8):1104-11. PubMed ID: 26733283
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
[TBL] [Abstract][Full Text] [Related]
13. Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study.
Valtcheva N; Nguyen-Sträuli BD; Wagner U; Freiberger SN; Varga Z; Britschgi C; Dedes KJ; Rechsteiner MP
Exp Mol Pathol; 2021 Dec; 123():104705. PubMed ID: 34637782
[TBL] [Abstract][Full Text] [Related]
14. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
Ibrahim SS; Hafez EE; Hashishe MM
J Exp Clin Cancer Res; 2010 Jun; 29(1):82. PubMed ID: 20579331
[TBL] [Abstract][Full Text] [Related]
15. High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
Mazzuccato G; De Bonis M; Carboni V; Marchetti C; Urbani A; Scambia G; Capoluongo E; Fagotti A; Minucci A
Mol Biol Rep; 2020 Jun; 47(6):4897-4903. PubMed ID: 32468256
[TBL] [Abstract][Full Text] [Related]
16. BRCA-analyzer: Automatic workflow for processing NGS reads of BRCA1 and BRCA2 genes.
Kechin A; Khrapov E; Boyarskikh U; Kel A; Filipenko M
Comput Biol Chem; 2018 Dec; 77():297-306. PubMed ID: 30408727
[TBL] [Abstract][Full Text] [Related]
17. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.
Takano EA; Mitchell G; Fox SB; Dobrovic A
BMC Cancer; 2008 Feb; 8():59. PubMed ID: 18298804
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel.
Laitman Y; Borsthein RT; Stoppa-Lyonnet D; Dagan E; Castera L; Goislard M; Gershoni-Baruch R; Goldberg H; Kaufman B; Ben-Baruch N; Zidan J; Maray T; Soussan-Gutman L; Friedman E
Breast Cancer Res Treat; 2011 Jun; 127(2):489-95. PubMed ID: 20960228
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of DNA extraction methods and real time PCR optimization on formalin-fixed paraffin-embedded tissues.
Dedhia P; Tarale S; Dhongde G; Khadapkar R; Das B
Asian Pac J Cancer Prev; 2007; 8(1):55-9. PubMed ID: 17477772
[TBL] [Abstract][Full Text] [Related]
20. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
